How to Prepare Clinical Evaluation Documentation for Medical Device Registration in South Korea

For medical device registration in South Korea, clinical evaluation documentation cannot be prepared in isolation — it should be built on four confirmations made before drafting begins: the target market and submission route, the product's risk classification, the applicable regulatory pathway, and the existing documentation base. Only after these are settled should a company assess its technical file, quality management system evidence, labelling and instructions for use (IFU), local representative arrangements, clinical evidence, and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete evidence, or undefined authorization arrangements do not extend the overall project timeline. For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a gap assessment first, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused.

Published: 2026-07-15 16:24  |  Updated: 2026-07-15 16:24

Key Takeaways

Questions about how to prepare clinical evaluation documentation for South Korea registration are usually driven by a practical need: to judge whether existing documentation can support a submission in the target market, whether a local agent or authorized representative is required, why timelines are extended, and which issues could affect the launch plan. These questions typically involve product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities at the same time.

Registration in a target market affects the technical file, authorized representative arrangements, importer coordination, label language, quality system evidence, and subsequent change control. If a project is driven only by the question of "which documents must be submitted," it is easy to encounter deficiency letters or rework in areas such as model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends treating this question within a broader GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than rebuilding documentation country by country.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for a single country is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence, and labelling and IFU, and then localize them according to each country's regulatory requirements.

Applicable Scenarios and Core Questions

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, method and duration of body contact, whether it is sterile, whether it is active, and whether it contains software or has IVD characteristics, and then determine the risk classification and submission pathway. If the pathway assessment is wrong, all downstream activities — translation, notarization, authorization, testing, and supplementary documentation — will move in the wrong direction.

For any target-market project, the applicant entity and local responsibility boundaries must also be clarified: who holds the certificate, who handles regulatory communication, who manages importation and post-market events, who triggers changes, and who maintains renewal documentation. If these points are left unclear in a commercial contract, market control can easily be compromised later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or other applicable quality system evidence, technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labelling and IFU, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, model coverage of test reports, the applicable scope of clinical evidence, risk management conclusions, label warnings, and information in the registration application form must support one another. What regulators assess is whether the product is safe, effective, and traceable for its intended use in the target market — not how many documents have been uploaded.

Common Mistakes

• Translating NMPA documentation directly and submitting it without restructuring the evidence according to the target market pathway.
• Listing too many models and specifications while test reports, clinical evidence, or labelling do not cover all of them.
• Selecting a local agent purely on commercial sales criteria, without defining regulatory responsibilities, certificate control, and post-market maintenance duties.
• Inconsistency between labels, IFU, promotional materials, and registration claims, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, resulting in duplicated preparation for each country and inflated cost and timelines.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission. The checklist should cover:

• Target product list, model and specification matrix, and intended use statements.
• Review of existing NMPA, CE, FDA, or other market registration documentation for reusability.
• ISO 13485 certificate, test reports, risk management, clinical evaluation, and English-language IFU.
• Responsibilities, costs, certificate control, and exit mechanisms of the local agent or authorized representative.
• A target-country gap assessment table specifying what must be re-tested, translated, notarized, or supported by additional declarations.

AIMEILI's Perspective

AIMEILI advises companies not to treat target-market registration as a one-off document submission, but to manage it as an overseas market access program. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, and then converting it according to national requirements, is generally faster and more stable than preparing documentation on an ad hoc basis for each country — and it also supports later changes and renewals more effectively.

From a project management perspective, three items should be controlled as early as possible: first, product classification and pathway assessment; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, a project may still encounter repeated rounds of deficiency responses, agent communication, and post-market maintenance issues, no matter how extensive the documentation appears.

Frequently Asked Follow-up Questions

Can domestic registration documentation be used directly for target-market registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as-is. Companies need to adjust the documentation structure, language, labelling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target markets and the product list. The earlier the gap assessment is completed, the easier it is to schedule re-testing, translation, label adjustment, and agent selection in advance.

Why does the choice of local agent affect registration quality?

Local agents typically participate in regulatory communication, change management, certificate renewal, and post-market event handling. Unclear rights and responsibilities can affect certificate control and the stability of subsequent market operations.

Project Execution Recommendations

When executing this type of registration project, companies should maintain a project tracker that manages the product list, model specifications, registration pathway, documentation owners, translation status, testing status, local agent communication records, and estimated submission dates in a single table. This allows documentation gaps to be identified in a timely manner and helps management judge whether the project will affect the launch plan.

For companies that already hold registrations in several countries, an evidence reuse matrix should also be established to define which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labelling and IFU, clinical evaluation, risk management, performance verification, and quality system certificates in particular must remain version-consistent.

• Confirm target markets and the product list.
• Complete risk classification and pathway assessment.
• Establish a documentation gap assessment table.
• Define the local agent and certificate control arrangements.
• Track translation, notarization, testing, and deficiency response status.
• Assign post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards, and technical file are consistent. If the scope of the ISO 13485 certificate does not match the products being registered, or if the manufacturing site, model specifications, or IFU version do not match the test reports, a company may be asked for supplementary explanations even if it has prepared a large volume of documentation.

Before submission, companies should create an evidence consistency checklist that matches the product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and IFU version, and quality system certificate item by item. This step appears basic, but it can noticeably reduce the probability of deficiency letters, particularly for projects involving simultaneous submissions in multiple GHWP member states or multiple product families.

Localization and Representative Responsibilities

Target-market registration projects usually involve a local agent, authorized representative, importer, or registration holder arrangement. Companies must confirm in advance whether the local partner is responsible only for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and long-term market stability.

Labelling, IFU, and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already hold CE, FDA, NMPA, or other market documentation, the focus of localization is to convert reusable evidence into a submission structure acceptable in the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is finished. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest heavily in obtaining the certificate but overlook post-market maintenance; when a manufacturing site change, model expansion, IFU update, or agent replacement occurs later, the certificate can become disconnected from actual market sales.

AIMEILI recommends managing this issue within an annual international registration plan: first define target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only improved efficiency for registration in a single country, but also the development of a repeatable overseas compliance capability that reduces the cost of starting from scratch each time a company enters a new market.

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only as supplementary reference. Scope of application: this article is intended for preliminary understanding, documentation preparation, and project planning, and does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal advice.

Compiled from the AIMEILI registration practice question bank, the medical device international registration knowledge base, and publicly available regulatory information; specific projects should be based on the latest requirements of the target country's regulatory authority and the product's documentation base.